NewGenIVF gains in premarket; looks to address convertible-note issue
NewGenIVF soared 20.4% to $0.70 Tuesday and was indicated at $1.07 premarket after announcing a $7.38 million settlement to repurchase convertible notes and warrants from JAK Opportunities VI LLC, aiming to cut dilution risk; payments run through late 2027, and default could restore dilution threats, shifting focus to the company’s ability to meet the payment schedule.